BioSpace News Archive

As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.

Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from China’s Harbour BioMed.

Kura Oncology has spun out Caspian around KO-7246, which seeks to increase the number and activity of beta cells in the pancreas, in turn boosting insulin production in patients with diabetes.

An analysis of 1,961 expiring patents, 682 clinical trials and a decade of deal activity finds competitive advantage in oligonucleotide therapeutics moving off the sequence and onto delivery, conjugation and manufacturing.

Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.

A career setback can teach you something useful—or teach you the wrong lesson. Executive coach Angela Justice explains how one difficult experience can quietly shape the choices that follow.

Biotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.